Released February 20, 2020 | SUGAR LAND
en
North Carolina remains a favorite for investment in pharmaceutical-biotech facilities. The Tar Heel State has 151 active project reports with a total investment value of $7.7 billion.
Three of the biggest drug companies in the world account for more than $3 billion of the total: Novo Nordisk leads the spending with its $2 billion investment in an active pharmaceutical ingredient (API) facility in Clayton; Merck has a $650 million project at its Gardasil vaccine site in Durham; and Pfizer is investing $500 million on a genetic therapeutics site in Sanford.
Click here for a list of pharmaceutical and biotech projects in North Carolina, and see graph below for a breakdown by project type.
Three of the biggest drug companies in the world account for more than $3 billion of the total: Novo Nordisk leads the spending with its $2 billion investment in an active pharmaceutical ingredient (API) facility in Clayton; Merck has a $650 million project at its Gardasil vaccine site in Durham; and Pfizer is investing $500 million on a genetic therapeutics site in Sanford.
Click here for a list of pharmaceutical and biotech projects in North Carolina, and see graph below for a breakdown by project type.
